BITTERZ
Today (November 1), on behalf of Bitterz LLC (Hinds Building, Kingstown, St. Vincent and the Grenadines), we are pleased to announce that our global crypto exchange Bitterz in Japan will start to provide services to our customers in China, Hong Kong and Taiwan.
To celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
We hope that you will enjoy the experience of trading with our Japanese crypto exchange with these bitcoins.
Bitterz Official Website
https://bitterz.com/refs/top/10457
▪ Main features of Bitterz
1. A safe environment to continue trading
Bitterz is a completely Japanese crypto exchange, which is rare among global exchanges.
We offer a trading environment suitable for accumulating wealth, with a leverage of 200 times at most, a zero-cut system, and a reliable support system.
2. All the developers are Japanese
Bitterz's system development team is all Japanese and was formerly a group of engineers from a large, privately held company.
3. MT5: a specialized tool in cryptocurrency
With the fast response of MT5, we have achieved a stress-free trading environment.
You won't miss the trading timing even in the rapidly changing cryptocurrency market.
4. A highly secured trading environment
We have 24-hour-monitoring for dealing and security, a cold wallet to protect your holdings, and a two-step authentication system to prevent unauthorized logins, creating a highly secure trading environment.
Your cryptocurrency holdings are insured; with a multi-sig cold wallet, your holdings can only be transferred under multiple administrators’ approval.
Most of your holdings will be managed in the cold wallet, as we plan to store several days of withdrawals in the hot wallet.
5. Reliable support system
We offer the fastest support in the industry with native staffs from China and Taiwan to provide you with a secure trading environment.
6. Demo account for trading experience
You can experience cryptocurrency trading in the same environment as real trading without using your own money.
This is a great option for those who want a risk-free trading experience and who want to see how easy it is to use the tools in advance.
7. A reassuring zero-cut system
We have adopted a zero-cut system, where even in case of unexpected loss, there is no additional deposit in excess of your holdings, so you can trade proactively without worries.
8. Withdrawal (transfer) fees are practically free forever
There are many exchanges that don't charge a withdrawal (transfer) fee, but most of them require you to pay a mining fee.
Of course, we will never charge you a fee for withdrawal.
In addition, in order not to burden our clients with mining fees, we pay you back with MT5 bonus credit, which makes withdrawal (transfer) fees practically free.
9. Enrichment of campaigns
We aim to provide some kind of campaign at all times throughout the year.
Now, to celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
For more information, please visit the official website below.
Bitterz Official Website
https://bitterz.com/refs/top/10457
View source version on businesswire.com: https://www.businesswire.com/news/home/20201101005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom